2024
Depression - Treatment Options and Managing Depression in Primary Care.
Anderson E, Crawford C, Fava M, Ingelfinger J, Sanacora G, Scott-Vernaglia S, Teel J. Depression - Treatment Options and Managing Depression in Primary Care. New England Journal Of Medicine 2024, 390: e44. PMID: 38749042, DOI: 10.1056/nejmp2310180.Peer-Reviewed Original ResearchDepression - Understanding, Identifying, and Diagnosing.
Anderson E, Crawford C, Fava M, Ingelfinger J, Nikayin S, Sanacora G, Scott-Vernaglia S, Teel J. Depression - Understanding, Identifying, and Diagnosing. New England Journal Of Medicine 2024, 390: e41. PMID: 38692291, DOI: 10.1056/nejmp2310179.Peer-Reviewed Original Research
2012
Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients
Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C. Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients. Biological Psychiatry 2012, 72: e27-e28. PMID: 22771240, PMCID: PMC3786174, DOI: 10.1016/j.biopsych.2012.05.031.Peer-Reviewed Original Research
2001
CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS
Krystal J, D'Souza D, Sanacora G, Goddard A, Charney D. CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS. Medical Clinics Of North America 2001, 85: 559-577. PMID: 11349473, DOI: 10.1016/s0025-7125(05)70329-1.Peer-Reviewed Original Research
2000
Impairment of GABAergic Transmission in Depression: New Insights from Neuroimaging Studies
Sanacora G, Mason G, Krystal J. Impairment of GABAergic Transmission in Depression: New Insights from Neuroimaging Studies. Critical Reviews In Neurobiology 2000, 14: 23. PMID: 11253954, DOI: 10.1615/critrevneurobiol.v14.i1.20.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNeurobiology of depressionGABAergic functionTechnique of PETCSF GABA concentrationsGABA-mimetic agentsNovel neuroimaging techniquesNondepressed comparison subjectsMood stabilizingChronic administrationGABAergic transmissionGABAergic neurotransmissionAntidepressant propertiesGABAergic abnormalitiesDepressed patientsAntidepressant drugsDisorder pathophysiologyLower plasmaComparison subjectsAnimal studiesGABAergic contributionGABA concentrationNovel imaging techniqueNeuroimaging studiesNeuroimaging techniquesDepression
1998
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography
Malison R, Price L, Berman R, van Dyck C, Pelton G, Carpenter L, Sanacora G, Owens M, Nemeroff C, Rajeevan N, Baldwin R, Seibyl J, Innis R, Charney D. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography. Biological Psychiatry 1998, 44: 1090-1098. PMID: 9836013, DOI: 10.1016/s0006-3223(98)00272-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsBrainBrain StemCarrier ProteinsCocaineDepressive DisorderFemaleHumansMaleMembrane GlycoproteinsMembrane Transport ProteinsMiddle AgedNerve Tissue ProteinsParoxetinePsychiatric Status Rating ScalesSerotoninSerotonin Plasma Membrane Transport ProteinsTomography, Emission-Computed, Single-PhotonConceptsDepressed patientsMajor depressionHealthy subjectsBrain serotonin transporter availabilitySerotonin transporterBeta-CIT SPECTDensity of brainPost-mortem brain tissuePathophysiology of depressionSerotonin transporter availabilityUnipolar major depressionBeta-CIT bindingSingle photon emissionSerotonergic neuronsBrain uptakeSERT availabilityTransporter availabilityBeta-CITBrain tissueCarbomethoxy-3βPatientsBlood plateletsDepressionPhoton emissionSignificant reduction